Hematologic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
URGENTseq enables the reporting of selected genes useful for immediate diagnosis (CALR, CSF3R, JAK2, KRAS, MPL, NPM1, NRAS, SF3B1) and treatment decisions (IDH1, IDH2) in hematologic malignancies within 48 hours of specimen collection.
|
30577887 |
2019 |
Hematologic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies.
|
30455381 |
2019 |
Hematologic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Since 2013, several mutant IDH-targeted inhibitors have been developed, and nearly a dozen clinical trials have opened specifically for IDH-mutant hematologic malignancies.
|
29064021 |
2017 |
Hematologic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Inhibition of mutant IDH shows promise as a treatment approach in hematologic malignancies, with further development ongoing in solid tumors and glioma.
|
27005468 |
2016 |
Hematologic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
IDH1- and IDH2-mutant primary human AML cells were more sensitive than IDH1/2 wild-type cells to ABT-199, a highly specific BCL-2 inhibitor that is currently in clinical trials for hematologic malignancies, both ex vivo and in xenotransplant models.
|
25599133 |
2015 |
Hematologic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Mutations in the IDH1 and IDH2 (isocitrate dehydrogenase) genes have been discovered across a range of solid-organ and hematologic malignancies, including acute myeloid leukemia, glioma, chondrosarcoma, and cholangiocarcinoma.
|
24760710 |
2014 |
Hematologic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The importance of the TET-mediated cytosine demethylation pathway is also underscored by a recurrent mutation of isocitrate dehydrogenase 1 (IDH1) and IDH2 in hematological malignancies, whose mutation inhibits TET function through a novel oncometabolite, 2-hydroxyglutarate.
|
25040794 |
2014 |
Hematologic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The somatic mutations of isocitrate dehydrogenase genes (IDH1 and IDH2) have been identified in a proportion of hematologic malignancies.
|
21997850 |
2012 |
Hematologic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Somatic mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) were recently demonstrated in acute myeloid leukemia (AML), but their prevalence and prognostic impact remain to be explored in large extensively characterized AML series, and also in various other hematologic malignancies.
|
20538800 |
2010 |
Hematologic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In this study, we screened the IDH1 and IDH2 mutations in a cohort of 456 Chinese patients with various hematological malignancies and disorders.
|
20946881 |
2010 |
Hematologic Neoplasms
|
0.400 |
CausalMutation
|
group |
CGI |
|
|
|